Cargando…

Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a substantial number of high-profile papers in the field of cancer biology. The papers, which were published between 2010...

Descripción completa

Detalles Bibliográficos
Autores principales: Haven, Babette, Heilig, Elysia, Donham, Cristine, Settles, Michael, Vasilevsky, Nicole, Owen, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775209/
https://www.ncbi.nlm.nih.gov/pubmed/26905833
http://dx.doi.org/10.7554/eLife.09462
_version_ 1782419025027923968
author Haven, Babette
Heilig, Elysia
Donham, Cristine
Settles, Michael
Vasilevsky, Nicole
Owen, Katherine
author_facet Haven, Babette
Heilig, Elysia
Donham, Cristine
Settles, Michael
Vasilevsky, Nicole
Owen, Katherine
author_sort Haven, Babette
collection PubMed
description The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a substantial number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington et al., 2014). This Registered Report describes the proposed replication plan of experiments from “A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations” by Sharma and colleagues, published in Cell in 2010 (Sharma et al., 2010). Sharma and colleagues demonstrated that prolonged exposure of cancer cells to TKIs give rise to small populations of “drug tolerant persisters” (DTPs) (Figure 1B-C) that were reversed during subsequent maintenance under drug-free conditions (Figures 1E, 2B and 2E). DTPs exhibited reduced histone acetylation and sensitivity to HDAC inhibitors (HDIs) (Figure 4A-B). Drug sensitivity was restored with co-treatment of either HDIs or an IGF-1R inhibitor, in combination with TKIs (Figure 5A-B). Inhibition of IGF-1R activation also led to decreased KDM5A expression and restoration of H3K4 methylation, suggesting a direct link between the IGF-1R signaling pathway and KDM5A function (Figure 7A, 7C, and 7I). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published in eLife. DOI: http://dx.doi.org/10.7554/eLife.09462.001
format Online
Article
Text
id pubmed-4775209
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-47752092016-03-07 Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Haven, Babette Heilig, Elysia Donham, Cristine Settles, Michael Vasilevsky, Nicole Owen, Katherine eLife Biochemistry The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a substantial number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington et al., 2014). This Registered Report describes the proposed replication plan of experiments from “A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations” by Sharma and colleagues, published in Cell in 2010 (Sharma et al., 2010). Sharma and colleagues demonstrated that prolonged exposure of cancer cells to TKIs give rise to small populations of “drug tolerant persisters” (DTPs) (Figure 1B-C) that were reversed during subsequent maintenance under drug-free conditions (Figures 1E, 2B and 2E). DTPs exhibited reduced histone acetylation and sensitivity to HDAC inhibitors (HDIs) (Figure 4A-B). Drug sensitivity was restored with co-treatment of either HDIs or an IGF-1R inhibitor, in combination with TKIs (Figure 5A-B). Inhibition of IGF-1R activation also led to decreased KDM5A expression and restoration of H3K4 methylation, suggesting a direct link between the IGF-1R signaling pathway and KDM5A function (Figure 7A, 7C, and 7I). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published in eLife. DOI: http://dx.doi.org/10.7554/eLife.09462.001 eLife Sciences Publications, Ltd 2016-02-23 /pmc/articles/PMC4775209/ /pubmed/26905833 http://dx.doi.org/10.7554/eLife.09462 Text en © 2016, Haven et al http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Biochemistry
Haven, Babette
Heilig, Elysia
Donham, Cristine
Settles, Michael
Vasilevsky, Nicole
Owen, Katherine
Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
title Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
title_full Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
title_fullStr Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
title_full_unstemmed Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
title_short Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
title_sort registered report: a chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
topic Biochemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775209/
https://www.ncbi.nlm.nih.gov/pubmed/26905833
http://dx.doi.org/10.7554/eLife.09462
work_keys_str_mv AT havenbabette registeredreportachromatinmediatedreversibledrugtolerantstateincancercellsubpopulations
AT heiligelysia registeredreportachromatinmediatedreversibledrugtolerantstateincancercellsubpopulations
AT donhamcristine registeredreportachromatinmediatedreversibledrugtolerantstateincancercellsubpopulations
AT settlesmichael registeredreportachromatinmediatedreversibledrugtolerantstateincancercellsubpopulations
AT vasilevskynicole registeredreportachromatinmediatedreversibledrugtolerantstateincancercellsubpopulations
AT owenkatherine registeredreportachromatinmediatedreversibledrugtolerantstateincancercellsubpopulations
AT registeredreportachromatinmediatedreversibledrugtolerantstateincancercellsubpopulations